TNNI3 and acute coronary syndrome: We recently reported the primary outcome from a multicenter randomized, controlled trial evaluating the impact of implementing a hs-cTnI assay on clinical outcomes in consecutive patients with suspected acute coronary syndrome.14 The introduction of hs-cTn reclassified 1 in 6 patients with myocardial necrosis who were not identified by the previous generation troponin assay, but this was not associated with an improvement in outcomes.